Clinical Trials
COVID-19, Schizophrenia, Dementia And Depression
SyneuRx is conducting several late-phase clinical trials in COVID-19 and schizophrenia disease areas.
Trials for dementia and depression will be launched in the near future
This is a Phase 2 trial testing the safety and efficacy of Pentarlandir for early and mildly symptomed COVID-19 patients. The antiviral efficacy for Pentarlandir covers different variants of COVID-19 since Pentarlandir targets two essential conservative enzymes during virus replication.
This is a Phase 2/3 trial testing the safety and efficacy of NaBen as a add-on therapy for adult schizophrenia. The trial is currently ongoing in the US, EU, and Taiwan.
NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid. NaBen is the first breakthrough therapy designation for schizophrenia approved by the US FDA.
This is a Phase 2/3 trial testing the safety and efficacy of NaBen as a add-on therapy for adults schizophrenia who are not responding to at least 2 existing antipsychotics. The trial is currently ongoing in the US, EU, and Taiwan.
NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid. The treatment for refractory schizophrenia is designed as NaBen plus clozapine.
This is a Phase 2/3 trial testing the safety and efficacy of NaBen as a add-on therapy for adolescent schizophrenia. The trial is currently ongoing in the US, EU, and Taiwan.
NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid. NaBen treatment for adolescent schizophrenia has been granted as orphan drug by the US FDA.